To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

NCT03795701 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Obesity

Interventions

DRUG: Saxenda®
OTHER: Placebo

Sponsor

Texas Tech University

Collaborators

[object Object]